WO1997033599A1 - Fish oil and garlic nutritive composition - Google Patents
Fish oil and garlic nutritive composition Download PDFInfo
- Publication number
- WO1997033599A1 WO1997033599A1 PCT/US1996/010500 US9610500W WO9733599A1 WO 1997033599 A1 WO1997033599 A1 WO 1997033599A1 US 9610500 W US9610500 W US 9610500W WO 9733599 A1 WO9733599 A1 WO 9733599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- approximately
- fish oil
- garlic
- capsaicin
- rutin
- Prior art date
Links
- 235000021323 fish oil Nutrition 0.000 title claims abstract description 52
- 235000004611 garlic Nutrition 0.000 title claims abstract description 28
- 244000245420 ail Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title description 32
- 230000000050 nutritive effect Effects 0.000 title description 3
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims abstract description 92
- 229960002504 capsaicin Drugs 0.000 claims abstract description 46
- 235000017663 capsaicin Nutrition 0.000 claims abstract description 46
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 41
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 41
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 41
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 41
- 235000005493 rutin Nutrition 0.000 claims abstract description 41
- 229960004555 rutoside Drugs 0.000 claims abstract description 41
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 21
- 108010010234 HDL Lipoproteins Proteins 0.000 claims abstract description 16
- 102000015779 HDL Lipoproteins Human genes 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 10
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 9
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 6
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract 17
- 210000002381 plasma Anatomy 0.000 claims abstract 3
- 239000007937 lozenge Substances 0.000 claims description 60
- 240000002234 Allium sativum Species 0.000 claims description 26
- 229940029982 garlic powder Drugs 0.000 claims description 23
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 235000006486 human diet Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 28
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 13
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 208000024172 Cardiovascular disease Diseases 0.000 description 11
- 230000009467 reduction Effects 0.000 description 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 7
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 235000004626 essential fatty acids Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229940013317 fish oils Drugs 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 240000009164 Petroselinum crispum Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 fish oils Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 235000011957 flavonols Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000011197 perejil Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940093797 bioflavonoids Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241000208293 Capsicum Species 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940064987 lemon bioflavonoid Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940103160 rutin 50 mg Drugs 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
Definitions
- the present invention provides a novel composition for preventing cardiovascular diseases in the human system, and more specifically to nutritive compositions containing fish oil, garlic, rutin, and capsaicin that reduce the levels of triglycerides, cholesterol, and low density lipoprotein (LDL) in the human blood serum, and increase the levels of high density lipoprotein (HDL) in human blood serum.
- nutritive compositions containing fish oil, garlic, rutin, and capsaicin that reduce the levels of triglycerides, cholesterol, and low density lipoprotein (LDL) in the human blood serum, and increase the levels of high density lipoprotein (HDL) in human blood serum.
- Cardiovascular disease resulting from the buildup of arterial plaque is known to be a leading cause of illness and death in humans.
- Arterial plaque is caused by precipitous material formed chiefly of oxidized low density lipoprotein (0- LDL) .
- the buildup of plaque in the form of O-LDL in the arteries is understood to be a factor in ischemic heart disease.
- Free radical oxidants many of which come from naturally occurring sources such as sun exposure, metabolism of certain nutrients, exercise, or are otherwise often observed in persons suffering from diabetes and high blood pressure, act to oxidize LDL into its deleterious form, 0-LDL.
- Free radical "scavengers" such as vitamins A, E, C, and selenium are believed to react with these oxidants and render them incapable of oxidation.
- HDL high density lipoprotein
- EFAs Essential fatty acids
- EPA eicosapantaenoic acid
- DHA docosahexaenoic acid
- EFAs such as EPA and DHA are known precursors of eicosanoids -- a class of compounds which includes prostanoids such as prostaglandins and thromboxanes, leukotrienes, and hydroxy fatty acids. Eicosanoids are known are known to affect platelet aggregation, permeability and tone of the blood vessel walls, blood pressure, and inflammatory immune reactions. [Gerster, cited above] .
- Glycogen storage disease is an inherited disorder, and is often complicated by severe hyperlipoproteinemia and hypercholesterolemia, which increase the risk of premature atherosclerosis and cardiovascular diseases. It has been reported that patients suffering from glycogen storage disease that received 10 grams of fish oil for 3 months experienced a significant decrease in levels of triglycerides in the blood serum (-49%) and cholesterol levels in the blood serum (-23%) , and a reduction in LDL levels in the blood serum (-40%) , and a significant increase in HDL levels in the blood serum (+30%). [Levy, E., et al. , I. Am. J. Clin. Nutr.. .57:922-29 (1993)] .
- Garlic powder has been proposed to have a number of valuable benefits to the human body as a preventative against cardiovascular diseases. For example, daily ingestion of garlic leads to reduced levels of lipids in human blood serum, increased fibrinolysis and tissue plasminogen activator (t-PA) activity, and decreased plasma fibrogen viscosity, each of which may lessen the likelihood of cardiovascular disease.
- t-PA tissue plasminogen activator
- Flavonoids are secondary metabolites which are found in edible plants and foodstuffs derived from plants. Flavonoids are widely recognized as having antiallergic, anti-inflammatory, antiviral, antiproliferative and anticarcinogenic activities. [Manach, C, et al. J. Nutr. , 125:1911-22 (1995)]. Among flavonoids, flavonols occur most abundantly in plants as possess most of these biological properties. [Manach, cited above]. Flavonols naturally occur as O-glycides, typically having a sugar moiety bound at the C-3 position. Rutin is the principal glycoside form of quercetin, the most abundant flavonol in fruits and vegetables.
- Capsaicin is a prominent chemical entity in plants of the Capsicum genus, which include chili peppers, red pepper, and paprika. Capsaicin is actually a class of compounds of branched- and straight-chain alkyl vanillylamides. The antimicrobial and analgesic properties of capsaicin have been known for centuries. In addition, capsaicin-containing products have been used to treat rheumatoid arthritis, osteoarthritis, diabetic neuropathy, postherpetic neuralgia, postmastectomy pain syndrome, cluster headache, and reflex sympathetic syndrome. [Cordell, G. and Araujo, 0. , Ann. Pharm.. 2_7:330-36 (1993)].
- compositions used to reduce the risks of cardiovascular disease are known, the present invention comprises a novel combination of fish oil, garlic, rutin, and capsaicin, which achieve this purpose. As such, there remains a need in the art for novel compositions like those of the present invention which may be used to treat or prevent cardiovascular disease and disorders.
- the present invention relates to the use of nutritional supplement compositions to overcome the nutritional deficiencies typically associated with the normal Western diet.
- the compositions of the present invention are obtained by combining fish oil, garlic powder, rutin, and capsaicin.
- the present invention relates to the daily co-administration of one preparation of fish oil, preferably as a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in a single lozenge.
- compositions which will increase the levels of HDL in human blood serum. It is a further object of the invention to provide compositions which will decrease levels of O-LDL in human blood serum.
- LDL should act to reduce the risk of heart disease in humans.
- compositions of the present invention are aimed at reducing the rate of occurrence of heart disease and are comprised of: (1) fish oil; (2) garlic powder; (3) rutin; and (4) capsaicin. More specifically, the compositions of the present invention are a combination of a fish oil preparation, preferably in the form of a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in the form of a single lozenge which is co-administered with the fish oil lozenge.
- the preferred weight of the fish oil lozenge is between about 500 mg and about 1500 mg, preferably about 1000 mg.
- the preferred weight of the garlic lozenge is between about 400 mg and about 1000 mg, and most preferably about 700 mg.
- the fish oil preparation component of the compositions of the present invention may be available from commercial sources. [Arista, Pharmachem] .
- EPA and DHA are the active moieties of the fish oil preparation.
- the fish oil preparation of the present invention comprises EPA in the amount of about 250 mg to about 350 mg, and most preferably about 300 mg.
- the remainder of the fish oil preparation comprises from about 150 mg to about 250 mg of DHA, and preferably about 200 mg of DHA.
- the total weight of the fish oil preparation of the present invention is from about 500 mg to about 1500 mg, and preferably about 1000 mg per fish oil lozenge when in the form of a single fish oil lozenge.
- the garlic powder used in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may be obtained from commercially available sources. [Extracts, Ashland, Pure-Gar] .
- a pharmaceutically acceptable form of garlic powder used in the compositions of the present invention comprises, by weight, from about 100 mg to about 700 mg, and more preferably about 175 mg to about 650 mg, and most preferably 500 mg of deodorized and aged garlic powder per garlic/rutin/capsaicin lozenge when in the form of a single lozenge.
- the rutin which is employed in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may also be obtained from commercially available sources. [Westco Chemical, Freeman Industries, Inc.] .
- the rutin component of the garlic powder, rutin, and capsaicin preparation comprised, by weight, from about 10 mg to about 150 mg, and most preferably about 100 mg.
- Capsaicin which is used in the compositions of the present inventions may be commercially obtained. [AllChem, Good Hope Botanicals] .
- the capsaicin component of the compositions of the present invention comprises, by weight, from about 20 mg to about 150 mg, and most preferably about 100 mg of capsaicin.
- the garlic powder, rutin, and capsaicin components are admixed in the same preparation. This preparation is co- administered with the fish oil preparation -- the two preparations comprising the compositions of the present invention. These preparations may be made by conventional methods.
- compositions of the invention are combined as the active ingredient in intimate admixture with a suitable carrier according to conventional compounding techniques.
- This carrier may take a wide variety of forms depending upon the form of preparation desired for administration, e.g., oral, sublingual, nasal, or parenteral.
- any of the usual pharmaceutical media may be employed.
- oral liquid preparations e.g., suspensions, elixirs, and solutions
- media containing for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used.
- Carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to prepare oral - solids (e.g., powders, capsules, pills, tablets, and lozenges) .
- Lozenges are a preferred oral dosage form. Controlled release forms may also be used.
- lozenges, tablets, pills, and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
- tablets may be sugar coated or enteric coated by standard techniques.
- additional inactive components which provide for easier oral administration include but are not limited to lemon bioflavonoids [Botanical International, Freeman], parsley powder, d-alpha tocopherol, bee's wax, lecithin, gelatin, purified water, and glycerin. These compounds may be used in creating the lozenges of the novel nutritional supplements.
- the carrier will usually comprise sterile water, although other ingredients may be included, e.g., to aid solubility or for preservation purposes.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.
- a preferred method for using the present invention is for the user to ingest, daily from about 4 to 8 lozenges of the fish oil preparation, most preferably about 6 lozenges of the fish oil preparation, together with from about 3 to 5 lozenges of the garlic powder, capsaicin and rutin preparation, and most preferably 4 lozenges of the garlic powder, capsaicin and rutin preparation.
- the following examples illustrate the preferred embodiments of the present invention. These examples are illustrative only, and do not purport to limit the invention in any fashion.
- EXAMPLE 1 The effect of the present invention on the human lipid profile was measured. A double blind study carried out at the University of California at Irvine Medical School showed that the proper use of the present invention provides for the following effects in human blood serum: (1) a significant reduction in triglyceride levels; (2) a significant decrease in cholesterol and LDL; and (3) a significant increase in the levels of HDL.
- the protocol followed during this investigation was as follows. Ten subjects participated in a month-long study wherein each subject ingested ten lozenges for each day of the study.
- the placebo group used 10 nonactive lozenges each day for one month, and the active group ingested 10 lozenges of the present invention each day for one month.
- EXAMPLE 2 The following example provides a preferred composition of the present invention.
- the composition is provided as two separate preparations: lozenge A (fish oil) and lozenge B (garlic, capsaicin, and rutin) .
- the proper daily dosage is six of lozenge A and four of lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges) .
- the following example provides a preferred composition of the present invention.
- the composition is provided as two separate preparations: Lozenge A (fish oil) and Lozenge B (garlic, capsaicin, rutin) .
- the proper dosage is six capsules of Lozenge A each day and four capsules of Lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges) .
- EXAMPLE 4 The following example provides a preferred composition of the present invention.
- the composition is provided as a single preparation.
- the proper dosage is five capsules of the lozenge taken twice each day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96921665A EP0835119A4 (en) | 1996-03-12 | 1996-06-17 | Fish oil and garlic nutritive composition |
AU62827/96A AU6282796A (en) | 1996-03-12 | 1996-06-17 | Fish oil and garlic nutritive composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2517396P | 1996-03-12 | 1996-03-12 | |
US60/025,173 | 1996-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997033599A1 true WO1997033599A1 (en) | 1997-09-18 |
Family
ID=21824477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/010500 WO1997033599A1 (en) | 1996-03-12 | 1996-06-17 | Fish oil and garlic nutritive composition |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0835119A4 (en) |
CN (1) | CN1190347A (en) |
AU (1) | AU6282796A (en) |
WO (1) | WO1997033599A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015237A1 (en) * | 1998-09-15 | 2000-03-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
KR20030080340A (en) * | 2002-04-08 | 2003-10-17 | 주식회사 엔바이오제네시스 | Manufacture method of diet food involving capsicin |
FR2849992A1 (en) * | 2003-01-17 | 2004-07-23 | Inst Phytoceutic | COMPOSITION FOR ORAL ADMINISTRATION CONTAINING CAPSAICINOIDS |
EP1902723A1 (en) * | 2006-09-19 | 2008-03-26 | Jürgen Prof. Dr. Schrezenmeir | Medicament comprising an extract from capsicum, garlic and/or sabal as lipase inhibitor |
WO2025017264A1 (en) | 2023-07-20 | 2025-01-23 | Microphyt | Novel use of an extract of the microalga phaeodactylum tricornutum |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101103966B (en) * | 2006-07-14 | 2010-11-03 | 上海展望科技有限公司 | Omega-3 falty acid-garlic oil capsule and manufacturing method thereof |
CN104208454A (en) * | 2014-06-30 | 2014-12-17 | 江苏伟楼生物科技有限公司 | Garlic oil softgel and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3350M (en) * | 1963-12-23 | 1965-05-31 | Medicinali D U R S T S R L Fab | Association of nicotinic acid n-oxide with rutin and vitamin e as anti-lipemic remedies and promoting fibrinolytic activity. |
US4680313A (en) * | 1984-06-11 | 1987-07-14 | Ajinomoto Co., Inc. | Acceleration of lipid metabolism using vanillylamine derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6211079A (en) * | 1985-07-08 | 1987-01-20 | Nobutsugu Kimura | Compounded food good for blood vessel system |
JPH0817673B2 (en) * | 1991-08-06 | 1996-02-28 | 卓蔵 松山 | Activated garlic paste, method for producing the same, and foods using the same |
-
1996
- 1996-06-17 EP EP96921665A patent/EP0835119A4/en not_active Withdrawn
- 1996-06-17 WO PCT/US1996/010500 patent/WO1997033599A1/en not_active Application Discontinuation
- 1996-06-17 AU AU62827/96A patent/AU6282796A/en not_active Abandoned
- 1996-06-17 CN CN96195324A patent/CN1190347A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3350M (en) * | 1963-12-23 | 1965-05-31 | Medicinali D U R S T S R L Fab | Association of nicotinic acid n-oxide with rutin and vitamin e as anti-lipemic remedies and promoting fibrinolytic activity. |
US4680313A (en) * | 1984-06-11 | 1987-07-14 | Ajinomoto Co., Inc. | Acceleration of lipid metabolism using vanillylamine derivatives |
Non-Patent Citations (5)
Title |
---|
DATABASE HCAPLUS ON STN, No. 1985:606162, NEGULESCO J.A. et al., "Capsaicin Lowers Plasma Cholesterol and Triglycerides of Lagomorphs", Abstract No. 103:206162, 1985. * |
DATABASE WPIDS ON STN, DERWENT INFORMATION LTD., AN 66-18025F, (MEDI-N) FAB MEDICINALI DURS, "Rutine Vitamin E Deriv Complexes"; & FR,M,3 350, (1968). * |
DATABASE WPIDS ON STN, DERWENT INFORMATION LTD., AN 87-192446, BORRETZEN B. et al., "Refined Fish Oil Concentrate Contg. Omega-three Fatty Acid Ester(s) - Used in Treating Thrombotic Illness and Lowering Blood Cholesterol Level"; & WO,A,87 03899, (1987). * |
DATABASE WPIDS ON STN, DERWENT INFORMATION LTD., AN 95-084298, (OTAT-I) OTA T, "Garlic Emulsion for Reducing Cholesterol Level and Preventing Hypertension, Etc.- is Prepared from Powder of Garlic, Fish Oil, Perilla Oil and Stabiliser"; & JP,A,07 008 201, (1995). * |
See also references of EP0835119A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015237A1 (en) * | 1998-09-15 | 2000-03-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
KR20030080340A (en) * | 2002-04-08 | 2003-10-17 | 주식회사 엔바이오제네시스 | Manufacture method of diet food involving capsicin |
FR2849992A1 (en) * | 2003-01-17 | 2004-07-23 | Inst Phytoceutic | COMPOSITION FOR ORAL ADMINISTRATION CONTAINING CAPSAICINOIDS |
WO2004064542A1 (en) * | 2003-01-17 | 2004-08-05 | Institut Phytoceutic | Composition for oral administration containing capsaicinoids |
US7892582B2 (en) | 2003-01-17 | 2011-02-22 | Institut Phytoceutic | Composition for oral administration containing capsaicinoids |
EP1902723A1 (en) * | 2006-09-19 | 2008-03-26 | Jürgen Prof. Dr. Schrezenmeir | Medicament comprising an extract from capsicum, garlic and/or sabal as lipase inhibitor |
WO2025017264A1 (en) | 2023-07-20 | 2025-01-23 | Microphyt | Novel use of an extract of the microalga phaeodactylum tricornutum |
FR3151183A1 (en) | 2023-07-20 | 2025-01-24 | Microphyt | New use of an extract of the microalgae Phaeodactylum tricornutum |
Also Published As
Publication number | Publication date |
---|---|
CN1190347A (en) | 1998-08-12 |
AU6282796A (en) | 1997-10-01 |
EP0835119A4 (en) | 1998-08-26 |
EP0835119A1 (en) | 1998-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6326031B1 (en) | Method of decreasing cholesterol and triglycerides levels with a composition containing fish oil, garlic, rutin, and capsaicin | |
US6440464B1 (en) | Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates | |
US6054128A (en) | Dietary supplements for the cardiovascular system | |
US5976548A (en) | Nutritional supplement composition and use | |
US20020146463A1 (en) | Health promoting compositions | |
WO2001049285A1 (en) | Flavonoid drug and dosage form, its production and use | |
EP0265046A1 (en) | Balanced fiber composition | |
KR102038810B1 (en) | Growth hormone secretion promoter | |
JP2008297209A (en) | Lipid metabolism improving composition | |
US20050233944A1 (en) | Arginine compositions for coordinate modification of multiple cardiovascular risk factors | |
JPH11246399A (en) | Lipid metabolism improving composition | |
JP2004321171A (en) | Food and drink | |
JPH08225453A (en) | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same | |
US20190134165A1 (en) | Compositions and methods for treating thyroid disease | |
EP0835119A1 (en) | Fish oil and garlic nutritive composition | |
WO1998000024A1 (en) | Nutritional supplement composition and use | |
US6506420B2 (en) | Combinations of psyllium and chitosan for synergistic adsorption of triglyceride | |
EP4181693A1 (en) | Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function | |
WO2007121584A1 (en) | Food product containing policosanols | |
Silverman Jr et al. | Clinical and lymphocyte responses to beta-carotene supplementation in 11 HIV-positive patients with chronic oral candidiasis | |
JP2003095968A (en) | Circulatory disease-preventing composition | |
RU2194523C1 (en) | Curative-prophylactic complex | |
US6787162B1 (en) | Method and composition for regulation of blood cholesterol | |
JP2009234984A (en) | Agent for inhibition of lowering or for ameliorating renal function | |
KR20010026440A (en) | Composition for alcohol-detoxification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96195324.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 311485 Country of ref document: NZ |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996921665 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996921665 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
NENP | Non-entry into the national phase |
Ref document number: 97532557 Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996921665 Country of ref document: EP |